Alto Neuroscience has risen nearly tenfold in a single year, carrying with it the weight of extraordinary expectation. The company's ALTO-207 program now stands as both its greatest promise and its most consequential test — a reminder that in biotech, the distance between a compelling story and a proven one is measured not in quarters, but in clinical outcomes and regulatory verdicts. For those arriving late to this ascent, the question is no longer whether the company has momentum, but whether the price of belief has grown too steep.